Asset Details
Do you wish to reserve the book?
Heterogeneity of chemosensitivity in esophagea cancer using ATP-tumor chemosensitivity assay
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Heterogeneity of chemosensitivity in esophagea cancer using ATP-tumor chemosensitivity assay
Do you wish to request the book?
Heterogeneity of chemosensitivity in esophagea cancer using ATP-tumor chemosensitivity assay
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Heterogeneity of chemosensitivity in esophagea cancer using ATP-tumor chemosensitivity assay
2012
Overview
Aim： Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients. This study was aimed to demonstrate the degree of heterogeneity of chemosensitMty in esophageal cancers. Methods： A total of 42 esophageal cancer specimens were collected. The heterogeneity of chemosensitivity in esophageal cancer specimens was examined using an ex vivo ATP-tumor chemosensitivity assay （ATP-TCA）. Results： Thirty eight specimens produced evaluable results （90.5%）. The most active single agent tested was nedaplatin, to which 28.9% of samples were sensitive. Combinations of chemotherapy agents exhibited much higher sensitivity： cisplatin＋paclitaxel was sensitive in 16 of 38 （42.1%） of samples, while nedaplatin＋paclitaxel was more effective, which was sensitive in 20 of 38 cases （52.6%）. Conclusion： There was a marked heterogeneity of chemosensitivity in esophageal cancer. Chemosensitivity testing may provide a practical method for testing new regimens before clinical trials in esophageal cancer patients.
